Ashland (NYSE:ASH – Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Wednesday, April 30th. Analysts expect Ashland to post earnings of $1.14 per share and revenue of $514.79 million for the quarter.
Ashland (NYSE:ASH – Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The basic materials company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.79 by ($0.51). Ashland had a negative net margin of 1.12% and a positive return on equity of 7.41%. During the same period last year, the firm earned $0.45 EPS. On average, analysts expect Ashland to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Ashland Stock Up 0.5 %
Shares of ASH opened at $53.37 on Tuesday. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -80.86, a PEG ratio of 1.14 and a beta of 0.70. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.27 and a current ratio of 2.52. The business’s fifty day moving average price is $55.63 and its two-hundred day moving average price is $68.09. Ashland has a 52 week low of $45.21 and a 52 week high of $102.50.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on ASH
Insider Buying and Selling
In related news, CEO Guillermo Novo purchased 31,294 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $64.24 per share, for a total transaction of $2,010,326.56. Following the completion of the transaction, the chief executive officer now owns 31,294 shares of the company’s stock, valued at approximately $2,010,326.56. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 1.02% of the stock is owned by company insiders.
About Ashland
Ashland Inc provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions.
Read More
- Five stocks we like better than Ashland
- The How And Why of Investing in Oil Stocks
- Best Defense Stocks in 2025… So Far
- Buy P&G Now, Before It Sets A New All-Time High
- Alphabet Rebounds After Strong Earnings and Buyback Announcement
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret?
Receive News & Ratings for Ashland Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ashland and related companies with MarketBeat.com's FREE daily email newsletter.